State of Alaska Department of Revenue raised its position in shares of West Pharmaceutical Services Inc. (NYSE:WST) by 8.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,679 shares of the medical instruments supplier’s stock after buying an additional 645 shares during the period. State of Alaska Department of Revenue’s holdings in West Pharmaceutical Services were worth $1,084,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC raised its stake in shares of West Pharmaceutical Services by 5.7% in the fourth quarter. Commonwealth Equity Services LLC now owns 3,856 shares of the medical instruments supplier’s stock worth $378,000 after acquiring an additional 208 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of West Pharmaceutical Services by 1.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 353,571 shares of the medical instruments supplier’s stock worth $34,658,000 after acquiring an additional 4,225 shares during the last quarter. Stifel Financial Corp raised its position in shares of West Pharmaceutical Services by 14.4% in the fourth quarter. Stifel Financial Corp now owns 23,776 shares of the medical instruments supplier’s stock valued at $2,326,000 after purchasing an additional 2,985 shares during the period. Two Sigma Advisers LP raised its position in shares of West Pharmaceutical Services by 33.9% in the fourth quarter. Two Sigma Advisers LP now owns 2,500 shares of the medical instruments supplier’s stock valued at $245,000 after purchasing an additional 633 shares during the period. Finally, MML Investors Services LLC raised its position in shares of West Pharmaceutical Services by 23.0% in the fourth quarter. MML Investors Services LLC now owns 3,706 shares of the medical instruments supplier’s stock valued at $363,000 after purchasing an additional 694 shares during the period. Institutional investors and hedge funds own 91.86% of the company’s stock.
In related news, VP Daniel Malone sold 4,458 shares of the stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $123.03, for a total transaction of $548,467.74. Following the transaction, the vice president now owns 33,478 shares of the company’s stock, valued at approximately $4,118,798.34. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 1.70% of the stock is currently owned by corporate insiders.
A number of equities analysts recently commented on WST shares. William Blair reaffirmed an “outperform” rating on shares of bluebird bio in a research report on Tuesday, April 23rd. Zacks Investment Research downgraded shares of Inflarx from a “buy” rating to a “hold” rating in a research report on Friday, May 3rd. Bank of America lifted their target price on shares of Universal Health Services from $158.00 to $165.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Jefferies Financial Group lifted their target price on shares of EXACT Sciences from $100.00 to $115.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $123.05.
Shares of NYSE:WST traded up $4.05 during trading on Friday, reaching $136.91. 652,547 shares of the company traded hands, compared to its average volume of 275,531. The stock has a market capitalization of $8.98 billion, a price-to-earnings ratio of 48.72, a price-to-earnings-growth ratio of 3.71 and a beta of 1.30. West Pharmaceutical Services Inc. has a 52-week low of $91.75 and a 52-week high of $135.46. The company has a quick ratio of 2.13, a current ratio of 2.88 and a debt-to-equity ratio of 0.19. The firm’s fifty day simple moving average is $122.62.
West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, July 25th. The medical instruments supplier reported $0.89 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.17. The business had revenue of $469.70 million during the quarter, compared to analysts’ expectations of $459.90 million. West Pharmaceutical Services had a return on equity of 16.38% and a net margin of 12.53%. The company’s revenue was up 5.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.70 EPS. On average, research analysts forecast that West Pharmaceutical Services Inc. will post 2.88 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, August 7th. Investors of record on Wednesday, July 24th will be paid a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a yield of 0.44%. The ex-dividend date is Tuesday, July 23rd. West Pharmaceutical Services’s payout ratio is 21.35%.
West Pharmaceutical Services Profile
West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.
Featured Article: How can you know how many shares are floating?
Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services Inc. (NYSE:WST).
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.